Zai Lab Announces First-Time Inclusion of KarXT and VYVGART Hytrulo® in China's 2026 National Reimbursement Drug List, Expanding Access to Key Growth Products
Zai Lab Announces First-Time Inclusion of KarXT and VYVGART Hytrulo® in China’s 2026 National Reimbursement Drug List, Expanding Access to Key Growth Products
Zai Lab Announces Participation in Investor Conferences in November 2026
Zai Lab Advances Atopic Dermatitis Candidate Toward Potential Quarterly Maintenance Dosing
Zai Lab Presents Positive First-in-Human Data for ZL-1503, a Novel IL-13/IL-31Rα Bispecific, Demonstrating Rapid and Sustained Inhibition of Key Atopic Dermatitis Biomarkers and Extended Serum Half-Life Supporting Less Frequent Dosing
Wall Street Analysts See a 40.17% Upside in Zai Lab Limited (ZLAB): Can the Stock Really Move This High?
Zai Lab Limited 2026 Q3 - Results - Earnings Call Presentation
Why Zai Lab Stock Is Up 12.7% And What's Next
Zai Lab (ZLAB) Draws Fresh Optimism, Is The Stock Still 24% Undervalued?
Zai Lab Ltd (ZLAB) Q3 2026 Earnings Call Highlights: Stabilizing China Business, Breakthrough ...
Zai Lab Q3 Earnings Call Highlights
Zai Lab Q3 Performance Meets Expectations With Pivotal 2027 Ahead, UBS Says
Zai Lab (ZLAB) Q3 2026 Earnings Call Transcript
Zai Lab Limited (ZLAB) Q3 2026 Earnings Call Transcript
Zai Lab Presents Updated Clinical Data Demonstrating Zocilurtatug Pelitecan (Zoci) Induces Clinically Meaningful Responses and a Manageable Safety Profile in Previously Treated Extrapulmonary Neuroendocrine Carcinomas
Zai Lab Limited (ZLAB) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
Zai Lab Announces Third Quarter 2026 Financial Results and Recent Corporate Updates
Zai Lab To Present Updated Data From Phase 1b/2 Trial Of Zocilurtatug Pelitecan Showing Clinically Meaningful, Durable Anti-Tumor Responses In Patients With Previously Treated Advanced Extrapulmonary Neuroendocrine Carcinomas At The North American Neuroendocrine Tumor Society Symposium
Zai Lab Q3 2026 Earnings Call Transcript
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.